Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics' stock price has increased by 235.95% from April 11, 2025, to April 10, 2026. On March 12, 2026, Capricor reported its fourth quarter and full-year 2025 financial results and provided a corporate update, which included Deramiocel's BLA being under FDA review with a PDUFA target action date of August 22, 2026, and the Phase 3 HOPE-3 trial meeting its primary and key cardiac endpoints. The company reported a decline in total revenue and an increased net loss, which led to a stock decline. The company announced the establishment of a new PDUFA date for the Deramiocel BLA on March 10, 2026. On March 9, 2026, Capricor's common stock was approved for uplisting to the Nasdaq Global Select Market. On February 24, 2026, Capricor announced that results from its Phase 3 HOPE-3 clinical study of Deramiocel in DMD were selected for a late-breaking oral presentation at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, and the HOPE-3 clinical study report was submitted to the FDA. Insiders have sold $4,509,940.00 in company stock with no insider buying, and short interest in Capricor has recently increased by 34.57%. Technical indicators suggest potential upward trends, with the Momentum Indicator moving above 0 on April 2, 2026, and the MACD turning positive on April 7, 2026. CAPR moved above its 50-day moving average on March 5, 2026, but broke above its upper Bollinger Band on March 9, 2026.

Traditional product demand seasonality is not a significant factor for Capricor Therapeutics. The company's revenue is currently $0, with future revenue dependent on the successful commercialization of its product candidates. Market-related seasonal trends, influenced by factors such as economic cycles, investor psychology, and calendar events, may affect biotech stocks, but these are not direct seasonality in the demand for Capricor's specific products or services.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on cell and exosome-based therapeutics for cardiovascular and rare diseases. The company addresses conditions characterized by inflammation, fibrosis, and tissue degeneration, particularly Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury. Its leading product candidate, Deramiocel (CAP-1002), is in late-stage clinical development for DMD. The company also has an exosome technology platform, including CAP-2003 and the proprietary StealthX™ platform, in preclinical development for various therapeutic applications.

Capricor Therapeutics is headquartered in San Diego, California, with additional operations in Beverly Hills, California. The company serves patients throughout the United States and collaborates with academic and clinical research institutions. Capricor has an agreement with Nippon Shinyaku Co., Ltd. for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan, subject to regulatory approval.

Capricor Therapeutics' reputation has been shaped by its progress in clinical development and regulatory milestones. Positive news, such as the successful Phase 3 HOPE-3 trial results for Deramiocel in DMD and the FDA's ongoing review of its BLA, contribute positively to the company's standing. There have been no publicly reported events in the past year that have negatively impacted Capricor Therapeutics' brand reputation.

Capricor Therapeutics' stock ownership includes institutional, insider, and retail investors. Institutional shareholders hold 47.68% of the stock, while Capricor Therapeutics insiders hold 67.73%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Point72 Asset Management, L.P., Suvretta Capital Management, Llc, Tang Capital Management Llc, Ra Capital Management, L.p., Susquehanna International Group, Llp, Geode Capital Management, Llc, and Fmr Llc. Nippon Shinyaku Co Ltd is the largest individual Capricor Therapeutics shareholder, owning 7.09 million shares, representing 12.33% of the company.